Chargement en cours...

553. A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir

BACKGROUND: Nucleoside reverse transcriptase inhibitors (NRTIs) may contribute to or exacerbate cardiovascular risk, bone loss, and renal dysfunction. Darunavir (DRV) and dolutegravir (DTG) have a high barrier to resistance and proven tolerability profile, but have not been well studied as part of a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Open Forum Infect Dis
Auteurs principaux: Verna, John, Austin, Stephen
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2018
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6255063/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.561
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!